The Personalized MRNA Cancer Vaccine From Moderna And Merck (Intismeran Combined With Keytruda) Will Receive Its First Approval From A Major Regulator (FDA Or EMA).

What Is The Moderna And Merck Personalized MRNA Cancer Vaccine?

The vaccine, known as intismeran (mRNA-4157), is an individualized therapy codeveloped by Moderna and Merck. It uses messenger RNA to encode neoantigens derived from a patient's own tumor. When combined with Keytruda (pembrolizumab), it aims to train the immune system to recognize and attack residual cancer cells after surgery.

Did The INTERPATH-001 Phase 3 Trial Meet Its Goals?

Yes. In August 2026, the companies announced that the Phase 3 INTERPATH-001 trial met its primary endpoints: recurrence-free survival and distant metastasis-free survival in patients with high-risk, advanced melanoma. According to the official press release from Moderna and Merck, these results support regulatory submissions.

What Did Earlier Phase 2 Data Show?

A prior Phase 2 study, published in The Lancet, demonstrated that intismeran plus Keytruda reduced the risk of recurrence or death by 49% compared with Keytruda alone in resected stage III/IV melanoma. This data formed the basis for the Phase 3 design.

When Will The FDA Or EMA Approve Intismeran With Keytruda?

Our forecast is a 70% probability of first approval by 2029. The companies stated they would submit applications following the August 2026 results. Standard FDA (BLA) and EMA review timelines range from 12 to 24 months, placing a likely decision between late 2028 and 2029. Leerink Partners analysts project peak annual sales of $1.4 billion by 2032.

What Are The Main Regulatory Hurdles?

Regulators will scrutinize manufacturing consistency for a personalized product. Each batch is unique to a patient, requiring validated quality controls. Additionally, the FDA previously paused federal funding for mRNA vaccine research in the U.S., though this did not halt the ongoing trial. The companies have confirmed their submission plans as of August 2026.

Which Other Cancers Could This Vaccine Target?

If approved for melanoma, the platform could expand to lung, pancreatic, and other solid tumors. Moderna has ongoing trials in these indications, but melanoma is the lead candidate.

Frequently Asked Questions

How Does Intismeran Differ From A Traditional Vaccine?

Unlike preventive vaccines, intismeran is therapeutic. It is manufactured by sequencing the patient's excised tumor, identifying up to 34 neoantigens, and encoding them into mRNA. The injection is given after surgery to prevent recurrence.

Is The Combination More Effective Than Keytruda Alone?

Yes, based on Phase 2 data showing a 49% reduction in recurrence risk, and the August 2026 Phase 3 results that confirmed statistically significant improvements in both recurrence-free and distant metastasis-free survival.

What Is The Expected Timeline For A Commercial Launch?

Assuming a 2029 approval by the FDA or EMA, launch would likely occur within 3 to 6 months after approval. Manufacturing scale-up for personalized mRNA is rapid, taking about 4 to 6 weeks per patient dose from tumor sample to final product.